Advancing the Therapeutic Pipeline in Alport Syndrome

Join the Kidney Health Initiative (KHI) for a mixer focused on the future of Alport syndrome therapies. Alport Syndrome Foundation will share updates from their December 2025 FDA campus meeting focused on ASSENT (Alport Syndrome Surrogate Endpoint Network), an international initiative with the goal of identifying surrogate endpoints that can be used in clinical trials to accelerate drug development and bring new therapies to patients with Alport syndrome. This session will highlight the status of the pharmaceutical pipeline in Alport syndrome, key challenges and opportunities in drug development for this rare genetic kidney disease, and how this patient organization is partnering with industry at every stage—from preclinical exploration to clinical trial design and patient recruitment. Don’t miss this opportunity to hear the latest insights and connect with others committed to accelerating treatments for the Alport community.